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490Clinical Utility of Computed Tomography Screening
of Chest, Abdomen, and Sinuses before Hematopoietic
Stem Cell Transplantation: The St. Jude Experience
Kimberly A. Kasow,1 Jennifer Krueger,1 Deo Kumar Srivastava,2 Chenghong Li,2
Raymond Barfield,1 Wing Leung,1 Edwin M. Horwitz,1 Renee Madden,1 Paul Woodard,1
Ishtiaq Hussain,3 M. Beth McCarville,3 Rupert Handgretinger,1 Gregory A. Hale1All allogeneic (allo) and autologous (auto) hematopoietic stem cell transplantation (HSCT) recipients at St.
Jude Children’s Research Hospital undergo pre-HSCT computed tomography (CT) of the sinuses, chest, and
abdomen because they are at significant risk for opportunistic infections. We studied whether this extensive
routine imaging is warranted to detect infection despite the risk of additional radiation exposure. We
reviewed the medical records of all children receiving allo- and auto-HSCT at St. Jude in 2004 and 2005.
Of the 184 eligible patients who received 187 transplants, 131 received allografts and 56 autografts. Solid
tumors and lymphomas were removed from the final analysis of the chest and abdomen CT as this imaging
is typically warranted as part of disease restaging; thus, 111 allogeneic participants were included in this anal-
ysis. Both auto- and allo-recipients were evaluated by sinus CTand included in this final analysis. Most allo-
and auto-HSCT recipients ($80%) did not have sinus, pulmonary, cardiac, or gastrointestinal symptoms;
.85% of the evaluable allo-recipients had no prior fungal infection. Eighty-eight allo- and 31 auto-HSCT
recipients had abnormal sinus CT findings, all unrelated to the underlying disease. Sixty-two (55.9%) of
the allo-recipients had normal chest CTand 85 (76.6%) had normal abdominal CT. Of the 18 allo-recipients
who began new therapy based on these findings, only 2 (11.1%) were related to chest CT findings and the
other 16 were related to sinus findings. Our findings suggest that pre-HSCT routine CT imaging of the
abdomen may not be warranted in a subset of allogeneic recipients who are asymptomatic and without
previous infectious findings. Thus, these patients may be spared unnecessary radiation exposure. Recipients
undergoing auto-HSCT or allo-HSCT for lymphomas or solid tumors will routinely undergo chest and
abdominal CT imaging as part of their disease evaluation. The decision to perform chest CT should be
made judiciously based on a careful history and physical examination. Sinus imaging, which was frequently
abnormal, may be justified in all patients to plan post-HSCT care.
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Patients undergoing hematopoietic stem cell
transplantation (HSCT) are at significant risk for tox-
icity following the procedure [1]. Bacterial, viral, and
fungal pathogens frequently infect these immunocom-
promised patients [1-4]; therefore, clinicians may feel
the need to screen patients for preexisting infections
to reduce the risk of post-HSCT infections. However,
the routine use of pre-HSCT radiographic imaging
has not been adopted by many. At St. Jude Children’s
Research Hospital, we have incorporated computed
tomography (CT) imaging of the sinuses, chest, and
abdomen into our pre-HSCT evaluation. Although
this imaging may detect an infection, it increases the
patient’s radiation exposure and complicates the
scheduling of the pre-HSCT evaluation. Moreover,
Biol Blood Marrow Transplant 15:490-495, 2009 491Utility of CT Imaging before HSCTthis radiologic modality may produce imaging arti-
facts, which may lead to unnecessary medical evalua-
tions or delays in HSCT.
It is especially important to compare the benefits
and risks of pre-HSCT radiographic imaging in chil-
dren who are at a rapid stage of growth and develop-
ment and are particularly sensitive to the current and
late effects of radiation [5,6]. To determine the utility
of clinical screening of the chest, abdomen, and sinuses
by CT, we retrospectively reviewed a large group of
consecutive pediatric and adolescent patients who un-
derwent autologous (auto) or allogeneic (allo) HSCT
at St. Jude from January 2004 to December 2005.PATIENTS AND METHODS
The study was approved by the St. Jude institu-
tional review board (IRB). We retrospectively re-
viewed the records of 195 consecutive children who
underwent HSCT at St. Jude between January 1,
2004, and December 31, 2005. All patients were
treated on institutional protocols approved by the
IRB or nonprotocol standard therapies. Written in-
formed consent was obtained from the patient, parent,
or legal parent before initiating therapy.
Medical records were reviewed for the date of CT
imaging; information regarding sinus, respiratory,
cardiac, and gastrointestinal symptoms at the time of
CT imaging; history of pretransplant fungal infection;
underlying disease or indication for transplant; disease
status at the time of transplant; absolute neutrophil
count at the time of CT imaging; imaging results;
date of transplant; and therapeutic interventions based
on these findings prior to transplant. Imaging findings
were categorized by the investigators as related if they
were because of the disease (or its treatment) for which
transplant was being performed. Otherwise, the find-
ings were categorized as unrelated.
Radiation Dose Estimation
At St. Jude, sinus CT is performed without IV con-
trast material by acquiring 2.5 mm-thick axial images
at 5 mm intervals, using 4 detectors (4  1.25 mm),
120 kilovoltage peak (kVp), 200 milliamperes (mA),
a tube rotation time of 0.5 s, and a 25 cm field of
view. Chest and abdomen CTs are obtained with i.v.
contrast material and helical acquisition of 5 mm-thick
images, using 120 kVp and mA modulated by body
part to a preset noise level of 5. Using these scanning
parameters we determined radiation exposure in
a 16-cm diameter phantom with a 100 mm long (3 cc
active volume) ionization chamber (Radcal 9095
dosimetry system, RADCAL Inc., Monrovia, CA).
The exposure measurement geometry captures radia-
tion from the primary beam falling on the ionization
chamber, as well as scatter radiation contributionfrom the phantom media, over the active length of
the ionization chamber. Exposure readings were
obtained in the middle and at the periphery of the
phantom by inserting the ionization chamber into
holes drilled into it. Exposure readings were then
multiplied by exposure to absorbed dose conversion
factors and length of the chamber and divided by the
collimation employed for measurement. This provides
the CT radiation absorbed dose descriptor computed
tomography dose index over a 100 mm length of
ionization chamber (CTDI100). To obtain a weighted
average of peripheral and central contributions to
dose we calculated theWeighted Computed Tomogra-
phy Dose Index (CTDIw). Next, we corrected the
CTDIw for clinical technique factors such as table
incrementation/pitch to obtain the volume computed
tomography dose index (CTDIvol). Finally, the
effective dose was obtained by applying age-specific
conversion factors as suggested by Shrimpton and
Wall [7]. This method is approved for pediatric CT
accreditation by the American College of Radiology [8].
The radiation dose associated with a particular
exam can be assessed by comparing it to background
radiation as a standard. In the United States, the aver-
age effective background radiation dose per year is
approximately 3.0 millisievert (mSv) [9,10].Statistical Methods
The demographic, clinical abnormalities, and
signs and symptoms for allo- and auto-HSCTs were
summarized using frequency tables. Logistic regres-
sion, with 1 covariate at a time, was used to evaluate
the predictors of abnormal CT findings of the chest,
abdomen, and sinus for allo- and auto-HSCTs. Values
of P # .05 were considered statistically significant. All
analyses were performed by using SAS v9.1 (SAS Insti-
tute Inc., Cary, NC).RESULTS
Patient Characteristics
Of the 195 eligible patients, 11 were excluded from
the final analysis: 1 had received a tandem transplant, 3
did not have pre-HSCT CTs, and 7 had undergone
imaging evaluation more than 2 months before
HSCT. Nine patients received multiple transplants:
6 had 2 allo-HSCTs, 2 had 1 allo- and 1 auto-
HSCT, and 1 had 2 allo- and 1 auto-HSCT. For those
receiving multiple HSCTs, the median duration from
1 HSCT to another was 6.5 months (range: 1.8-22.7
months). Of the 184 patients included in the final
analysis, 187 transplants were performed consisting
of 131 (70.1%) allo-HSCT and 56 (29.9%) auto-
HSCT. Three patients included in the final analysis
Table 1. Patient Demographics for Allogeneic (N 5 111)
Hematopoietic Stem Cell Transplantation (HSCT) Recipients
Characteristics N (%)
Sex
Female 42 (37.8%)
Male 69 (62.2%)
Race
Caucasian 58 (52.3%)
Black 22 (19.8%)
Others 31 (27.9%)
Age at transplant (year)
<3 16 (14.4%)
3-10 41 (36.9%)
11-17 37 (33.3%)
18-27 17 (15.3%)
Mean (standard deviation) 10.3 (6.1)
Median (range) 10.7 (0.5-21.7)
Product type
PBSC 54 (48.6%)
BM 57 (51.4%)
Diagnosis
CML 10 (9.0%)
Genetic disease 13 (11.7%)
Lymphoid malignancy 46 (41.4%)
Myeloid malignancy 42 (37.8%)
Donor type
Matched related (6/6) 23 (20.7%)
Mismatched related 54 (48.7%)
Matched unrelated (6/6) 33 (29.7%)
Mismatched unrelated 1 (0.9%)
Status
Alive 77 (69.4%)
Dead 34 (30.6%)
PBSC indciates peripheral blood stem cells; BM, bone marrow; CML,
chronic myelogenous leukemia.
Patients receiving an allogeneic HSCT for lymphoma or solid tumor or
an autologous HSCTwere excluded from this analysis.
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HSCT. Of the 131 allo-HSCT recipients, 51 (39%)
were female; 25 (45%) of the auto-HSCT recipients
were female. The median age of allo-HSCT recipients
was 10.9 years (range: 0.5-26.6 years) and the median
age of auto-HSCT recipients was 7.3 years (range:
1.5-26 years). Most patients receiving an allo-HSCT
had a hematologic malignancy (78.6%), whereas those
undergoing an auto-HSCT predominantly had solid
tumors (71.4%). All patients were included in the sinus
CT findings; patients with solid tumors and lympho-
mas were excluded from CT chest and abdomen
analyses, as these patients routinely undergo this
imaging as a part of disease evaluation. Thus, 111
allo-recipients, comprised of those with lymphoge-
nous (n 5 46) and myelogenous (n 5 52) hematologic
malignancies, and genetic disorders (n 5 13), were in-
cluded in the chest and abdomen CT analyses, and the
characteristics regarding these patients are outlined in
Table 1. Median absolute neutrophil count at the time
of CT imaging was 1400/mm3.
For 4 allogeneic patients, a history of fungal
infections was not known. Of the remaining 107 allo-
recipients, 95 (88.8%) had no history of fungal infec-
tion. Twelve recipients (11.2%) had a history of fungal
infection, and of these patients, 9 (75%) had only 1 site
of infection, 2 (16.7%) had 2 sites, and 1 (8.3%) had 3
sites of involvement. Eight patients (66.6%) had a pre-
vious pulmonary fungal infection, whereas 2 (16.7%)
had abdominal involvement and 2 (16.7%) had positive
blood cultures.
Most patients did not have underlying sinus
(86.5%, allo; 80%, auto), pulmonary (84.9%, allo;
94.6%, auto), cardiac (97.6%, allo; 96.4%, auto), or
gastrointestinal (95.2%, allo; 98.2%, auto) signs and
symptoms at the time of imaging.CT Findings
Figure 1A and B outlines chest and abdomen CT
findings for 111 allo-recipients. Of these allo-HSCT
patients, 62 of 111 (55.9%) had normal chest CT find-
ings. Of this group, only 5 of 62 (8.1%) had pulmonary
or cardiac symptomatology. Eighty-five of 111
(76.6%) patients had normal abdominal CT findings,
and of this group, only 3 of 85 (3.5%) had gastrointes-
tinal symptoms. There were abnormal sinus findings
in most of the allo- (67.2%) and auto-HSCT
(55.4%) recipients, which were unrelated to the under-
lying disease process.
Of the 8 patients with prior fungal pulmonary
infections, 6 (75%) had abnormal pre-HSCT chest
imaging. Only 4 of these patients had pulmonary or
cardiac symptoms at the time of imaging. One of 2
patients with prior abdominal fungal infections had
abnormal abdominal imaging pre-HSCT; only 1
had gastrointestinal symptoms at the time of CT.No auto-HSCT recipient had a history of fungal
infection.
We determined whether specific variables—sex,
race, age at transplant, underlying diagnosis, graft
product recipient was to receive, and type of donor—
predicted the risk of finding abnormalities on pre-
HSCT scans. Upon univariate analysis of the 111
allo-graft recipients, age at the time of transplant was
statistically significant for abnormal chest findings
(odds ratio 0.91 [0.85-0.79]; P5 .005). Age was further
categorized as\3versus$3and incorporated as a cova-
riate in the logistic model, and patients\3 years of age
were more likely to have abnormal chest CT findings
than patients $3 years of age (P 5 .002). No variable
showed statistical significance in those allo-recipients
who had abdominal CT scans performed.
Therapy was initiated based on pretransplant
imaging in a small fraction of patients. Although 18
of 111 allogeneic recipients with abnormal chest or
abdominal CT findings had new therapy, only 2 were
based on chest findings (11.1%). Of these 2 patients,
1 had a history of previous pulmonary fungal disease
and new therapy was initiated based on this pre-
HSCT finding (Figure 2A and B). Predominantly,
treatments were initiated based on abnormal sinus
Figure 1. Number of allogeneic (allo) patients categorized by pre-HSCT chest (A) and abdominal (B) CT findings: normal versus abnormal CT imaging
and classified further by symptomatology.
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ents). No patient had therapy initiated based on
abdominal findings.
The effective radiation dose estimates (in mSv)
based on age of patient for CT of the sinuses were
2.10 (1 years old), 1.64 (5 year old), 1.23 (10 years
old), 1.39 (15 years old), 1.62 (adult), and those for
CT of the chest and abdomen were 4.90 (1 year old),
4.20 (5 years old), 4.50 (10 years old), 4.60 (15 years
old), and 8.90 (adult).DISCUSSION
We undertook this retrospective study to deter-
mine whether pretransplant CTs of sinuses, chest,
and abdomen are warranted in detecting asymptomatic
infections in patients preparing to undergo auto- or
allo-HSCT. We found that routine imaging of theabdomen in asymptomatic, allogeneic patients was
unlikely to reveal any previously unknown abnormali-
ties or abnormalities requiring alterations in treatment
with respect to abnormal findings. Patients with solid
tumors and lymphomas routinely undergo this radio-
logic modality as part of their disease reevaluation
before HSCT, and therefore, were excluded from the
chest and abdomen CT analysis. Several transplant
recipients had unrelated chest abnormalities, such as
pericardial fluid, serosal thickening, and atelectasis;
however, only 2 patients received new therapy based
on these CT abnormalities. Six patients in the allo-
recipient cohort, ranging in age from 0.8 to 19.66
years, had atelectasis on chest CT, suggesting that
atelectasis is a cause of abnormal finding at any age.
Although this finding suggests that many of the chest
CT findings were incidental and did not change the
patient’s course of therapy, a clinician should also
consider the patient’s underlying disease, previous
Figure 2. Organizational diagrams of allogeneic (allo) HSCTrecipients who underwent pretransplant chest (A) and abdominal (B) CT imaging. Patients
were further characterized by history of fungal infection and symptomatology, followed by the initiation of new therapy based on CT findings. Only 2 new
therapies were started based on chest CT findings and none on abdominal findings.
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when determining the necessity of performing a pre-
HSCT chest CT. CT imaging of the sinuses was
frequently abnormal, even in asymptomatic patients.
In a previous report, severity of pre-HSCT sinusitis
as determined by CT correlated with symptomatology
and radiologic findings after HSCT [11]. Thus, rou-
tine detection of sinusitis before HSCT may allow
early initiation of antibiotic therapy, potentially lead-
ing to a reduction in significant posttransplant sinus
disease.
There are no other published studies on the utility
of pretransplant chest or abdominal screening by CT
for patients. Ours is the first study to document that
routine imaging of the chest and abdomen is unlikely
to detect clinically undetectable abnormalities or alter
management prior to HSCT. It can be argued that
a chest and abdomen CT before HSCT, particularlyfor an allogeneic recipient, provides a baseline for
comparison when post-HSCT scans are obtained
and abnormalities are noted. On the other hand,
clinically insignificant findings may delay transplant
while a workup of the abnormalities is pursued.
Children who are not able to lay still need to be sedated
for the imaging, and thus, anesthesia risks should also
be considered. Furthermore, the benefits of a pre-
HSCT chest and abdomen CT in asymptomatic
patients may not outweigh the risks of additional
radiation exposure. This is especially important when
children and adolescents are being treated—at a time
of rapid body development and organ growth, their
bodies may be more sensitive to the damaging effects
of radiation than those of adults [12]. Radiation carci-
nogenic effects resulting from diagnostic imaging pro-
cedures are stochastic. That is, there is no threshold
dose at which a malignancy is induced. Rather, the
Biol Blood Marrow Transplant 15:490-495, 2009 495Utility of CT Imaging before HSCTprobability of secondary malignancy increases with in-
creasing radiation exposure and is cumulative over
time. Radiation-induced malignancies, which may oc-
cur because of the additive effects of radiation therapy
as well as multiple radiographic images, may have long
latency periods, frequently spanning decades [10].
Thus, when considering the benefit to risk ratio of rou-
tine CT imaging examinations involving asymptom-
atic children, one should be careful in recommending
this imaging procedure if it is unlikely to result in alter-
ations in their clinical care. A more detailed statistical
analysis of this project was limited because of small
patient numbers, even at a large pediatric transplant
center.
Another limitation of this study is that it was per-
formed retrospectively and interventions, whether di-
agnostic or therapeutic, were at the discretion of the
primary transplant attending. Inmost cases with radio-
logic abnormalities, therapeutic interventions or fur-
ther diagnostic evaluations including cultures were
not performed; we do not know if this was the best
decision, but a medical decision nonetheless. Primary
attendings decided when to further investigate, and
the presence or absence of symptoms may have played
a factor in when physicians decided to investigate ab-
normalities. Furthermore, because of the retrospective
nature of this study, we do not know whether trans-
plants were delayed based onCTfindings. A delay pro-
ceeding to transplant could have occurred in patients
with abnormalities, but this is not definitively known.
Our findings suggest that routine CT screening of
the abdomen in asymptomatic patients undergoing
allo-HSCT rarely identifies new abnormalities that
are undetectable clinically and does not lead to signif-
icant changes in patient management. Performing
chest CTs should be decided judiciously based on
the individual patient’s history and current clinical
status. Routine CT imaging of the sinuses frequently
reveals abnormalities, and therefore may be considered
in autologous and allogeneic patients before transplan-
tation in concert with an otolaryngology consultation.ACKNOWLEDGMENTS
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